Skip to main content

Advertisement

SpringerLink
Log in

The business of developing antibacterials

  • Feature
  • Published:

From Nature Biotechnology

View current issue Submit your manuscript

Although some dazzling technical approaches have fallen short, dozens of small companies and a few major pharmas seek new products for this medically crucial, modest-growth market.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Figure 1: Vancomycin-resistant enterococci.

Centers for Disease Control and Prevention/Janice Car

Figure 2: Market for systemic antibacterials.
Figure 3: Antibacterial agents approved 1983–2007.

References

  1. Moore, A. The big and small of drug discovery. Biotech versus pharma: advantages and drawbacks in drug development. EMBO Reports 4, 114–117 (2003).

    Article  CAS  Google Scholar 

  2. Mygind, P.H. et al. Plectasin is a peptide antibiotic with therapeutic potential from a saprophytic fungus. Nature 437, 975–980 (2005).

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. freelance writer based in Washington, D.C.,

    Jeffrey L Fox

Authors
  1. Jeffrey L Fox
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Fox, J. The business of developing antibacterials. Nat Biotechnol 24, 1521–1528 (2006). https://doi.org/10.1038/nbt1206-1521

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1038/nbt1206-1521

  • Springer Nature America, Inc.

This article is cited by

Search

Navigation